Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis
Status:
Completed
Trial end date:
2016-12-20
Target enrollment:
Participant gender:
Summary
To determine whether secukinumab can alter the activity of cytochrome P450 (CYP) 3A4 using
midazolam as probe substrate in patients with moderate-to-severe plaque psoriasis.